BI201335

DRUG3 trials

Sponsors

Boehringer Ingelheim

Conditions

Hepatitis CHepatitis C, Chronic

Phase 1

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

CompletedNCT00793793

Boehringer IngelheimHepatitis C, Chronic

Start: 2007-09-30End: 2011-01-25Updated: 2018-09-05

Phase 3

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

CompletedNCT01297270

Boehringer IngelheimHepatitis C

Start: 2011-04-30End: 2014-04-30Updated: 2015-09-18

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

CompletedNCT01399619

Boehringer IngelheimHepatitis C, Chronic

Start: 2011-09-30End: 2014-06-30Updated: 2016-08-29

Related Papers

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.

2016-05-011 citations

Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.

2015-03-0112 citations

Viral Resistance in Hepatitis C Virus Genotype 1-Infected Patients Receiving the NS3 Protease Inhibitor Faldaprevir (BI 201335) in a Phase 1b Multiple-Rising-Dose Study

Antimicrobial Agents and Chemotherapy2013-07-2321 citations